LSL Pharma Group Appoints Luc Mainville as Chief Financial Officer
04 December 2023 - 11:30PM
LSL PHARMA GROUP INC (TSXV: LSL) ("the Company" or "LSL Pharma "),
a Canadian integrated pharmaceutical company, is pleased to
announce the appointment of Mr. Luc Mainville as Senior Vice
President and Chief Financial Officer effective December 4, 2023.
Mr. Mainville brings extensive experience in the
capital markets and life sciences industry. He is recognized for
his financial and operational leadership having been associated
with several fast-growing companies. In an executive management
career spanning more than 30 years, he has been involved in
numerous public and private financings totalling in excess of $500
million and more than 50 corporate transactions, including initial
public offerings, licensing, as well as mergers and
acquisitions.
Over the last five years, Mr. Mainville acted as
Senior Vice President and Chief Financial Officer of Valeo Pharma,
a fast-growing Canadian pharmaceutical company. During his tenure
at Valeo, he raised in excess of $100 million helping Valeo
increase its revenues 15 fold. Prior to that, he held senior
management positions with various life sciences companies,
including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB
Research. Prior to his career in the life sciences sector, he was
partner with KPMG, LLP. He holds an MBA from McGill University.
Luc Mainville has been Director of LSL Pharma
since February 2023, and will relinquish his board position when
joining the Company.
"The appointment of Luc Mainville represents an
important step in creating a best-in-class highly performant
management team at LSL Pharma," said François Roberge, President
and CEO of LSL Pharma. "Luc is a seasoned professional with an
excellent knowledge of the life sciences industry, capital markets
and public financings. We are delighted that he is joining us and
we are looking forward to benefitting from his extensive
experience. He will be a key contributor in carrying out our
strategy, which includes growing organically and through
acquisitions.”
CAUTION REGARDING FORWARD-LOOKING
STATEMENTS
This press release may contain forward-looking
statements as defined under applicable Canadian securities
legislation. Forward-looking statements can generally be identified
by the use of forward-looking terminology such as "may", "will",
"expect", "intend", "estimate", "continue" or similar expressions.
Forward-looking statements are based on a number of assumptions and
are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company's ability to control or
predict, that could cause actual results or performance to differ
materially from those expressed or implied in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, those identified in the Company's filings with Canadian
securities regulatory authorities, such as legislative or
regulatory developments, increased competition, technological
change and general economic conditions. All forward-looking
statements made herein should be read in conjunction with such
documents.
Readers are cautioned not to place undue
reliance on forward-looking statements. No assurance can be given
that any of the events referred to in the forward-looking
statements will transpire, and if any of them do, the actual
results, performance or achievements of the Company may differ
materially from those expressed or implied by the forward-looking
statements. All forward-looking statements contained in this press
release speak only as of the date of this press release. The
Company does not undertake to update these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
ABOUT LSL PHARMA GROUP
INC.
LSL Pharma is an integrated Canadian
pharmaceutical company specializing in the development,
manufacturing and distribution of high-quality natural health
products and dietary supplements in solid dosage forms, as well as
high-quality sterile ophthalmic pharmaceuticals. For further
information, please visit the following websites
www.groupelslpharma.com, www.laboratoirelsl.com and
www.sterimedpharma.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
CONTACT :François Roberge,
President and CEO Telephone: 514 664-7700E-mail:
Investors@groupelslpharma.com
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From Apr 2024 to May 2024
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From May 2023 to May 2024